EP0667168A1 — An inhalation training device
Assigned to Aradigm Corp · Expires 1995-08-16 · 31y expired
What this patent protects
An inhalation training device for maximizing the delivery of an airborne medication to receptor sites in a patient's lungs comprises inhaler means (100) including a source of airborne medication for inhalation by a patient, a flow measurement means (116) coupled with the inhaler …
USPTO Abstract
An inhalation training device for maximizing the delivery of an airborne medication to receptor sites in a patient's lungs comprises inhaler means (100) including a source of airborne medication for inhalation by a patient, a flow measurement means (116) coupled with the inhaler means (100) for measuring the flow of air through the inhaler means (100), a microprocessor means (124) for integrating the flow of air over a time to produce a measure of volume inhaled, storage means (126) for storing the measured flow and volume values and for storing additional quantifiable diagnostic parameters related to projected patterns of medication distribution to receptor sites in a patient's lungs, and display means (130) for providing a visual display of measured flow and volume values of the patient as well as said diagnostic parameters related to projected delivery of medication to receptor sites in the lungs of the patient and for contrasting measured values with desired levels for those values.
Drugs covered by this patent
- Cutivate (FLUTICASONE PROPIONATE) · Teva Pharm
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.